Merve Şahin

Merve Şahin

Auto-generated profile, based on publicly available information

Merve Şahin

Health Sciences University Adana City Training and Research Hospital Spec. } Adana ORCID

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in The Journal of Turkish Family Physician
Verified
Journal Article
Open access
PDF file
MŞMerve Şahin
Merve Şahin
Merthan TunayMerthan Tunay
Merthan Tunay
TTTuğba Tehçi
Tuğba Tehçi
Objective: In our study, anxiety level and quality of life were determined in patients with CSU and the variables affecting these two factors were analyzed. Materials and Methods: This cross-sectional study was conducted using face-to-face interviews with 66 patients who were diagnosed with CSU and admitted to the Dermatology Clinic of Adana City Training and Research Hospital in 2023. Results: 78.8% of the participants were female, the mean age was 40.22±12.82 years, and the mean duration of the disease was 5.36±6.05 years. The mean Urticaria Control Test (UCT) was 8.80±4.90, and 95.8% of the participants with good disease control received Omalizumab treatment (p=0.000). Participants with poorly controlled disease had a higher total score on the Beck Anxiety Scale (BAS) (11.40±7.41). The mean total score of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) was calculated as 45.17±15.52. Conclusion: The findings of our study reveal the relationship between impaired quality of life and anxiety levels with disease activity in patients with CSU. Even if not life-threatening from the patient’s perspective, the uncertainty of symptoms is uncomfortable and limits daily life. New generation drugs such as omalizumab may positively affect quality of life.